Skip to Content

Lariam (mefloquine) Disease Interactions

There are 4 disease interactions with Lariam (mefloquine):

Major

Mefloquine (applies to Lariam) psychosis/depression

Major Potential Hazard, High plausibility. Applicable conditions: Neurosis, History - Psychiatric Disorder

The use of mefloquine for malaria prophylaxis is contraindicated in patients with active depression, a recent history of depression, generalized anxiety disorder, psychosis, schizophrenia, or other major psychiatric disorders. Mefloquine may cause psychiatric symptoms in some patients, including agitation, anxiety, depression, mood changes, panic attacks, paranoia, confusion, hallucinations, aggression, and psychotic behavior. Occasionally, these symptoms have been reported to continue long after mefloquine has been withdrawn due to its long half-life. Rare cases of suicidal ideation and suicide have occurred during mefloquine use, although a causal relationship has not been established. Therapy with mefloquine should be administered cautiously in patients with a previous history of depression. Psychiatric symptoms that occur during prophylactic use such as acute anxiety, depression, restlessness, or confusion should be considered prodromal to a more serious event, and the drug must be discontinued and an alternative medication substituted.

References

  1. "Product Information. Lariam (mefloquine)." Roche Laboratories, Nutley, NJ.
Major

Mefloquine (applies to Lariam) seizures

Major Potential Hazard, High plausibility.

The use of mefloquine for malaria prophylaxis is contraindicated in patients with a history of seizures. Mefloquine can increase the risk of convulsions in patients with epilepsy and may lower the plasma levels of some anticonvulsant medications. Therefore, it should only be prescribed for curative treatment of malaria in such patients and only if there are compelling medical reasons for its use.

References

  1. "Product Information. Lariam (mefloquine)." Roche Laboratories, Nutley, NJ.
Moderate

Mefloquine (applies to Lariam) ECG abnormalities

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Heart Disease

Mefloquine is a myocardial depressant. Animal studies with parenteral mefloquine indicate that the drug possesses 20% of the antifibrillatory action of quinidine and produces 50% of the increase in the PR interval reported with quinine. The effect of mefloquine on the compromised cardiovascular system has not been evaluated. However, transient and asymptomatic ECG alterations have been reported during the use of mefloquine, including sinus bradycardia, sinus arrhythmia, first-degree AV block, prolongation of the QTc interval, and abnormal T waves. In postmarketing use, hypotension, hypertension, flushing, syncope, chest pain, tachycardia, palpitation, bradycardia, irregular pulse, extrasystoles, AV block, and other transient cardiac conduction alterations have been reported rarely. Therapy with mefloquine should be administered cautiously in patients with cardiac disease and only if potential benefits justify the risks.

Moderate

Mefloquine (applies to Lariam) liver disease

Moderate Potential Hazard, High plausibility.

Mefloquine is primarily metabolized by the liver. Patients with liver disease may be at greater risk for adverse effects from mefloquine due to decreased drug clearance. Therapy with mefloquine should be administered cautiously in patients with liver disease. Periodic evaluation of hepatic function should be performed during prolonged therapy.

References

  1. "Product Information. Lariam (mefloquine)." Roche Laboratories, Nutley, NJ.

Lariam (mefloquine) drug interactions

There are 369 drug interactions with Lariam (mefloquine)

Lariam (mefloquine) alcohol/food interactions

There is 1 alcohol/food interaction with Lariam (mefloquine)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.